Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome-Reference-Cited by-同舟云学术

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome

Published:2014-12-04 Issue:1 Volume:4 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Xu Feng,He Qi,Li Xiao,Chang Chun-Kang,Wu Ling-Yun,Zhang Zheng,Liu Li,Shi Wen-Hui,Zhu Yang,Zhao You-Shan,Gu Shu-Cheng,Fei Cheng-Ming,Guo Juan,Wu Dong,Zhou Liyu

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep07310.pdf

Reference32 articles.

1. Li, X., Bryant, C. E. & Deeg, H. J. Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. Int J Hematol 80, 140–1405 (2004).

2. Li, X., Song, Q. & Chen, Y. et al. Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis. PLoS One 9, e95473 (2014).

3. Fenaux, P., Mufti, G. J. & Hellstrom-Lindberg, E. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10, 223–232 (2009).

4. Kadia, T. M., Jabbour, E. & Kantarjian, H. Failure of hypomethylating agent- based therapy in myelodysplastic syndromes. Semin Oncol 38, 682–692 (2011).

5. Gumireddy, K., Reddy, M. V. & Cosenza, S. C. et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7, 275–286 (2005).

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic Approaches and Clinical Application of Representative Small-Molecule Inhibitors of Cyclin-Dependent Kinase for Cancer Therapy;Molecules;2024-06-26

2. Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy;JCI Insight;2024-05-30

3. Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy;2023-07-28

4. Rigosertib is more potent than wortmannin and rapamycin against adult T‐cell leukemia‐lymphoma;BioFactors;2023-06-22

5. DHX9-mediated pathway contributes to the malignant phenotype of myelodysplastic syndromes;iScience;2023-06